Mirikizumab: a landmark in IL-23-targeted therapy for ulcerative colitis
Open Access
- 10 November 2025
- journal article
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 9204-9205
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Cost per remission for mirikizumab versus ustekinumab for moderately to severely active ulcerative colitis treatment from the United States commercial payer perspectiveJournal of Medical Economics, 2025
- Anti-IL 12/23 versus Anti-Tumor Necrosis Factor-α in Patients with Biologically Naïve Crohn’s Disease: A Systematic Review and Meta-analysisInflammatory Intestinal Diseases, 2025
- An evaluation of mirikizumab for the treatment of ulcerative colitisExpert Opinion on Biological Therapy, 2024
- Targeting the Interleukin 23 Pathway in Inflammatory Bowel DiseaseGastroenterology, 2024
- Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension StudyInflammatory Bowel Diseases, 2024
- Ulcerative colitisThe Lancet, 2023
- Mirikizumab as Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2023